BVI has secured FDA approval for its FINEVISION HP trifocal intraocular lens (IOL), marking the US debut of a premium lens technology that has been implanted in millions of procedures worldwide over the past 15 years. The approval significantly expands the range of advanced lens options available to US ophthalmologists and their patients seeking vision correction after cataract surgery.
Established Global Technology Enters US Market
The FINEVISION HP represents one of the earliest trifocal intraocular lenses on the global market, featuring a diffractive optic design that supports vision at multiple distances including far, intermediate, and near vision. The third-generation lens integrates BVI's POD platform design and CoPODize technology to balance light distribution and reduce visual side effects, while incorporating a double C-loop with 4-point haptics to promote stable positioning within the capsular bag.
"FineVision HP redefined premium cataract surgery and continues to set the gold standard in premium IOL innovation," said Shervin Korangy, president and chief executive officer of BVI. "This FDA approval marks a pivotal step in expanding our IOL portfolio in the US, supporting our mission to deliver best-in-class visual outcomes for patients globally."
Clinical Evidence and Expert Perspectives
The FDA approval builds upon the lens's established international track record, supplemented by data from a US clinical study (NCT04176965) that evaluated the device's performance specifically for American patients. Study investigator Vance Thompson, MD, director of refractive surgery for Vance Thompson Vision in Sioux Falls, South Dakota, emphasized the clinical significance of the approval.
"The FINEVISION HP trifocal IOL reflects innovation in optic design, and I'm pleased to have been part of the US study evaluating its performance," Thompson stated. "This lens represents an important step forward in expanding advanced IOL choices for surgeons and their patients."
Damien Gatinel, MD, PhD, who oversees anterior segment and refractive surgery at the Rothschild Foundation in Paris, France, and was instrumental in the lens development alongside BVI's director of research and development Christophe Pagnoulle, highlighted the technology's transformative impact on the field.
"The development of [this lens] was a pivotal moment for ophthalmology, reshaping expectations for vision correction after cataract surgery," Gatinel said. "FDA approval in the US means even more patients will benefit from this breakthrough technology."
Market Introduction Strategy
BVI is implementing a methodical rollout strategy to manage the anticipated high demand for the FINEVISION HP. The company expects demand to exceed initial supply and has been investing in significant capacity expansion efforts to meet market requirements. A limited US rollout is planned starting fall 2025, with distribution expanding more broadly during the first six months of 2026.
The company will showcase the FINEVISION HP at the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida, from October 18-20, 2025, at booth number 3521, as part of its market introduction efforts.
Expanding US Portfolio
The FINEVISION HP approval represents a significant expansion of BVI's surgical portfolio in the US market. Earlier this year, the company received 510(k) clearance from the FDA for its laser endoscopy ophthalmic system (Leos), demonstrating BVI's broader commitment to bringing advanced ophthalmic technologies to American healthcare providers.
BVI, a diversified global ophthalmic device company with nine decades of experience developing leading products and solutions, partners with ophthalmic surgeons to improve vision for millions of patients across more than 90 countries worldwide. The company was recently honored with four distinctions at the 2025 Medical Device Network Excellence Awards, recognizing achievements in innovation, product launches, research and development, and investment initiatives.
